Part 1 is a dose escalation study by design, allowing the assessment of safety, tolerability and recommended dose levels of the combination of T-DXd and durvalumab plus cisplatin, carboplatin or pemetrexed. In part 2, expansions in the treatment naïve setting on any recommended dose level may take place to study preliminary efficacy as well.~The target population of interest are patients with advanced or metastatic non-small cell lung cancer measurable disease by RECIST criteria, HER2 overexpression, ECOG PS of 0 to 1, patients who have received 1 or 2 prior therapies for recurrent or metastatic disease (Part 1) and patients who are treatment naïve for recurrent or metastatic disease (Part 2)
DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with durvalumab and chemotherapy in patients with HER2 positive advanced and metastatic non-small cell lung cancer. The efficacy will be also analyzed as a secondary endpoint.